Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.86
IRWD's Cash to Debt is ranked higher than
59% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.74 vs. IRWD: 1.86 )
IRWD' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1.86

Equity to Asset 0.45
IRWD's Equity to Asset is ranked higher than
58% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. IRWD: 0.45 )
IRWD' s 10-Year Equity to Asset Range
Min: -1.86   Max: 0.74
Current: 0.45

-1.86
0.74
F-Score: 2
Z-Score: 1.49
M-Score: 813.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1101.36
IRWD's Operating margin (%) is ranked higher than
51% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.84 vs. IRWD: -1101.36 )
IRWD' s 10-Year Operating margin (%) Range
Min: -1101.36   Max: -48.43
Current: -1101.36

-1101.36
-48.43
Net-margin (%) -1192.31
IRWD's Net-margin (%) is ranked higher than
51% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. IRWD: -1192.31 )
IRWD' s 10-Year Net-margin (%) Range
Min: -1192.31   Max: -48.34
Current: -1192.31

-1192.31
-48.34
ROE (%) -713.70
IRWD's ROE (%) is ranked lower than
57% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. IRWD: -713.70 )
IRWD' s 10-Year ROE (%) Range
Min: -713.7   Max: -33.21
Current: -713.7

-713.7
-33.21
ROA (%) -97.80
IRWD's ROA (%) is ranked lower than
53% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. IRWD: -97.80 )
IRWD' s 10-Year ROA (%) Range
Min: -97.8   Max: -17.58
Current: -97.8

-97.8
-17.58
ROC (Joel Greenblatt) (%) -674.23
IRWD's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. IRWD: -674.23 )
IRWD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1389.65   Max: -176.8
Current: -674.23

-1389.65
-176.8
Revenue Growth (%) -25.80
IRWD's Revenue Growth (%) is ranked higher than
54% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. IRWD: -25.80 )
IRWD' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -25.8
Current: -25.8

EBITDA Growth (%) 52.00
IRWD's EBITDA Growth (%) is ranked higher than
97% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. IRWD: 52.00 )
IRWD' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 52
Current: 52

0
52
EPS Growth (%) 54.30
IRWD's EPS Growth (%) is ranked higher than
96% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. IRWD: 54.30 )
IRWD' s 10-Year EPS Growth (%) Range
Min: 0   Max: 54.3
Current: 54.3

0
54.3
» IRWD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

IRWD Guru Trades in Q2 2013

Paul Tudor Jones 20,400 sh (New)
Steven Cohen 11,045 sh (New)
Vanguard Health Care Fund 3,238,136 sh (+48.42%)
» More
Q3 2013

IRWD Guru Trades in Q3 2013

Steven Cohen 24,489 sh (+121.72%)
Vanguard Health Care Fund 3,348,268 sh (+3.4%)
Paul Tudor Jones Sold Out
» More
Q4 2013

IRWD Guru Trades in Q4 2013

Vanguard Health Care Fund 3,364,198 sh (+0.48%)
Steven Cohen Sold Out
» More
Q1 2014

IRWD Guru Trades in Q1 2014

John Burbank 16,207 sh (New)
Vanguard Health Care Fund 3,901,498 sh (+15.97%)
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-03-31 New Buy0.01%$11.43 - $15.35 $ 15.415%16207
Vanguard Health Care Fund 2013-06-30 Add 48.42%0.04%$9.93 - $18.17 $ 15.46%3238136
Lee Ainslie 2013-03-31 Sold Out 0.34%$11.08 - $18.85 $ 15.44%0
Lee Ainslie 2011-06-30 Reduce -35.91%0.18%$14.02 - $16.4 $ 15.42%2171197
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.00
IRWD's P/B is ranked higher than
58% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. IRWD: 11.00 )
IRWD' s 10-Year P/B Range
Min: 5.46   Max: 46.91
Current: 11

5.46
46.91
P/S 53.19
IRWD's P/S is ranked higher than
57% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.55 vs. IRWD: 53.19 )
IRWD' s 10-Year P/S Range
Min: 2.65   Max: 75.05
Current: 53.19

2.65
75.05
EV-to-EBIT -8.83
IRWD's EV-to-EBIT is ranked higher than
60% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IRWD: -8.83 )
IRWD' s 10-Year EV-to-EBIT Range
Min: 19.5   Max: 28
Current: -8.83

19.5
28
Current Ratio 9.64
IRWD's Current Ratio is ranked higher than
93% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. IRWD: 9.64 )
IRWD' s 10-Year Current Ratio Range
Min: 2.33   Max: 9.64
Current: 9.64

2.33
9.64
Quick Ratio 9.04
IRWD's Quick Ratio is ranked higher than
93% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. IRWD: 9.04 )
IRWD' s 10-Year Quick Ratio Range
Min: 2.33   Max: 9.04
Current: 9.04

2.33
9.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.80
IRWD's Price/Net Cash is ranked higher than
83% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IRWD: 19.80 )
IRWD' s 10-Year Price/Net Cash Range
Min: 8.78   Max: 1184
Current: 19.8

8.78
1184
Price/Net Current Asset Value 16.70
IRWD's Price/Net Current Asset Value is ranked higher than
79% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IRWD: 16.70 )
IRWD' s 10-Year Price/Net Current Asset Value Range
Min: 8.48   Max: 78.93
Current: 16.7

8.48
78.93
Price/Tangible Book 10.80
IRWD's Price/Tangible Book is ranked higher than
64% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.20 vs. IRWD: 10.80 )
IRWD' s 10-Year Price/Tangible Book Range
Min: 5.99   Max: 36.28
Current: 10.8

5.99
36.28
Price/Median PS Value 2.80
IRWD's Price/Median PS Value is ranked higher than
61% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. IRWD: 2.80 )
IRWD' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 2.97
Current: 2.8

0.16
2.97
Forward Rate of Return (Yacktman) -35.57
IRWD's Forward Rate of Return (Yacktman) is ranked higher than
52% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.93 vs. IRWD: -35.57 )
IRWD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.5   Max: 1.3
Current: -35.57

-0.5
1.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:I76.Germany
Ironwood Pharmaceuticals, Inc. was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. The Company currently operates its human therapeutics business segment- human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. Prior to the sale of its interest in Microbia, it also operated in the biomanufacturing segment. Its biomanufacturing segment, which comprised a much smaller part of its business, consisted of its majority ownership interest in Microbia. The Company's human therapeutics segment represented 100% of its total assets at December 31, 2011 and 2010. The Company is subject to federal, state, city and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for IRWD

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS Oct 27 2013 
Five-Year Lows: Singapore Airlines Limited, Gold Field Ltd., Ironwood Pharmaceuticals Inc., Northwes Oct 22 2013 
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 


More From Other Websites
AcelRx Pharmaceuticals (ACRX) Jumps: Stock Adds 11.7% in Session Jul 21 2014
Synergy Pharmaceuticals Progresses with Mid-Stage Candidate Jul 18 2014
Synergy Pharmaceuticals' Plecanatide to Move into Phase III Jul 09 2014
Coverage initiated on Ironwood Pharma by Furey Research Partners Jul 09 2014
Ironwood Pharmaceuticals to Host Second Quarter 2014 Investor Update Call Jul 07 2014
Ironwood Pharmaceuticals to Host Second Quarter 2014 Investor Update Call Jul 07 2014
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 26 2014
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 09 2014
Ironwood Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference Jun 05 2014
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 04 2014
Ironwood Pharmaceuticals Appoints Douglas Williams, Ph.D., to Board of Directors Jun 04 2014
Insider Trading Alert - TIF, CRM And IRWD Traded By Insiders Jun 02 2014
Ironwood has a conference call hosted by JPMorgan May 28 2014
High option volume stocks: GREK ATHL IRWD SANM RAX May 16 2014
Synergy Pharma Posts Narrower-than-Expected Q1 Loss May 14 2014
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2014 Healthcare Conference May 07 2014
IRONWOOD PHARMACEUTICALS INC Financials May 06 2014
An Encouraging Quarter, Ironwood One To Keep On The Radar In 2014 May 01 2014
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2014 May 01 2014
Ironwood Up as Loss Narrows, Linzess Shines Apr 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide